301225-86-5Relevant academic research and scientific papers
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: Modifications of the arylpropylpiperidine side chains
Lynch, Christopher L.,Willoughby, Christopher A.,Hale, Jeffrey J.,Holson, Edward J.,Budhu, Richard J.,Gentry, Amy L.,Rosauer, Keith G.,Caldwell, Charles G.,Chen, Ping,Mills, Sander G.,MacCoss, Malcolm,Berk, Scott,Chen, Liya,Chapman, Kevin T.,Malkowitz, Lorraine,Springer, Martin S.,Gould, Sandra L.,DeMartino, Julie A.,Siciliano, Salvatore J.,Cascieri, Margaret A.,Carella, Anthony,Carver, Gwen,Holmes, Karen,Schleif, William A.,Danzeisen, Renee,Hazuda, Daria,Kessler, Joseph,Lineberger, Janet,Miller, Michael,Emini, Emilio A.
, p. 119 - 123 (2007/10/03)
The 4-(3-phenylprop-1-yl)piperidine moiety of the 1,3,4-trisubstituted pyrrolidine CCR5 antagonist 1 was modified with electron deficient aromatics as well as replacement of the benzylic methylene with sulfones, gem-difluoromethylenes and alcohols in an effort to balance the antiviral potency with reasonable pharmacokinetics.
PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
-
, (2008/06/13)
The present invention is directed to pyrrolidine compounds of the formula I: (wherein R 1, R 2, R 3, R 4, R 5, R 6 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.
